Century Therapeutics (IPSC)

Century’s pipeline spans autoimmune disease and oncology. Its programmes include iPSC-derived beta islet cells for type 1 diabetes, iPSC-derived T cells and iPSC-derived natural killer cells. Beta islet cells are relevant to diabetes because they are involved in insulin production, while engineered immune cells such as T cells and NK cells are being explored for their ability to recognise and attack diseased cells, including cancer cells. The company applies cell engineering and manufacturing technologies to generate defined cell types from iPSCs and to optimise their potential therapeutic properties.

The company’s strategy reflects a broader trend in biotechnology toward next-generation cell therapies that can be produced in advance, stored and administered to many patients. If successful, allogeneic iPSC-derived products could address some of the logistical and cost challenges associated with personalised cell therapy. However, the field remains scientifically complex and highly regulated, with clinical development, safety, durability, immune compatibility and manufacturing scale-up all central risks.

For investors, Century Therapeutics is a clinical-stage life sciences stock tied to innovation in regenerative medicine, immuno-oncology and autoimmune treatment. Its value depends on progress across its iPSC platform, pipeline data, regulatory interactions, partnerships and the company’s ability to translate stem cell biology into viable therapies.